Hemab
Erik Bjornson currently serves as Vice President of Regulatory Affairs at Hemab Therapeutics, a position held since June 2023. Prior to this role, Erik was Head of Global Biologics Regulatory Strategy at Galderma from April 2022 to May 2023, and held the position of Senior Director of Global Regulatory Affairs at Sobi - Swedish Orphan Biovitrum AB (publ) from December 2021 to April 2022. Erik's extensive experience in regulatory affairs includes senior director roles at Takeda and Shire, as well as director-level positions at Baxalta and Baxter International Inc., where responsibilities included overseeing global regulatory strategies and compliance. Erik began a career in the industry as a Research Associate at the American Red Cross and holds a Bachelor of Science degree in Chemistry from Texas Christian University, earned between 1987 and 1991.
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.